21+ verification
All products are sold strictly for laboratory research use only and are not for human or animal consumption. You must be 21 or older to enter.
By entering you accept the research-use-only terms and confirm you are a qualified buyer.
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide, and the evidence behind it comes entirely from mice and cell cultures. Those studies show real, measurable drops in fat mass and improvements in NAD+ and SAM metabolism without appetite suppression. No human trials have tested it for safety or efficacy. Treat it as a promising research tool with an unproven translation to people.
TL;DR:
- 5-Amino-1MQ has only been tested in mice and cell cultures, showing fat loss and improved NAD+ and SAM metabolism without appetite suppression.
- It is a small-molecule enzyme inhibitor, often mislabeled as a peptide, and purity verification via certificates of analysis is essential.
- Animal studies used injectable dosing at high doses, and no human pharmacokinetic or safety data currently exist.
- Oral bioavailability appears species-dependent, with rat data suggesting feasibility but mouse data indicating poor absorption; human results are unavailable.
- As a research chemical, proper batch documentation and cautious interpretation of early data are critical before considering any human application.
5-Amino-1MQ is a quinolinium-based small molecule, chemically distinct from the amino acid chains that define a peptide. Its full name is 5-amino-1-methylquinolinium, and it’s most commonly sold in salt form as 5-amino-1-methylquinolinium iodide. Sigma-Aldrich’s product specification lists it at ≥98% purity by HPLC, with a defined molecular weight and CAS number that any legitimate supplier should be able to provide on request.
Here’s where the market gets sloppy. Search “5-amino-1MQ” and you’ll find it shelved next to BPC-157 and TB-500 on peptide vendor sites, marketed with the same language and often the same reconstitution instructions. That’s a category error. Peptides are chains of amino acids linked by peptide bonds. 5-Amino-1MQ has no amino acid backbone at all. It’s a synthetic organic compound in the same broad chemical family as other quinolinium derivatives being explored as enzyme inhibitors.
Why does the mislabeling happen? Mostly convenience. Vendors selling injectable peptides expanded into small molecules and kept the same catalog structure, the same “peptide” tab, and the same customer base without correcting the terminology. It’s a marketing shortcut, not a chemistry lesson, and it matters because a small molecule behaves completely differently in the body than a peptide does. Absorption, degradation, and dosing logic all change when you’re no longer talking about a chain of amino acids.
You’ll typically find 5-Amino-1MQ sold in three forms:
Whichever form you encounter, the certificate of analysis (COA) is the only real proof of what’s in the vial or capsule. A compound this chemically simple is also simple to cut or mislabel, so purity verification isn’t optional if the material is going into any kind of serious research protocol.
NNMT is an enzyme that methylates nicotinamide, the same molecule your body uses to build NAD+. Every time NNMT tags a nicotinamide molecule for clearance, it pulls that nicotinamide out of the NAD+ salvage pathway and consumes a molecule of SAM (S-adenosylmethionine) to do it. In tissues where NNMT is overactive, particularly fat and liver, this creates a double drain: less raw material for NAD+, and less SAM available for the hundreds of other methylation reactions cells depend on.
5-Amino-1MQ blocks that enzyme. Preclinical work published in PMC measured its potency against NNMT at an IC50 of approximately 1.2 μM, a strong number for a small-molecule inhibitor, and confirmed it’s membrane-permeable enough to reach the enzyme inside adipocytes and hepatocytes.
Block NNMT, and two things happen at once. Nicotinamide stays in the salvage pathway instead of getting tagged for excretion, so intracellular NAD+ levels rise. SAM stops getting consumed by an enzyme that was arguably working overtime in metabolically stressed tissue, so more of it becomes available for other methylation processes, including the kind that regulate gene expression. In the mouse studies, these shifts tracked with:
Here’s the number that matters most: that 1.2 μM IC50 is what makes 5-Amino-1MQ a useful research tool in the first place. Weaker inhibitors need higher concentrations to hit the target, which increases the odds of off-target effects contaminating the results.
None of this means the mechanism guarantees a clinical outcome. A clean biochemical pathway from enzyme inhibition to fat loss in a mouse is a necessary starting point, not proof that the same chain of events plays out the same way in human adipose tissue, human liver, and a human dosing schedule. Mechanism explains why something could work. It doesn’t confirm that it does, at scale, in people.
The foundational study here is the 2018 work from Neelakantan and colleagues, and it’s worth understanding exactly what it did and didn’t test. Researchers gave diet-induced obese mice 5-Amino-1MQ via subcutaneous and intraperitoneal injection, not orally, over a period of several weeks. The mice lost body weight, showed reduced white adipose mass, had smaller individual adipocytes, and saw plasma cholesterol drop. Critically, food intake didn’t change. The fat loss wasn’t a side effect of the mice simply eating less.
That last detail is what got researchers excited. An intervention that reduces adiposity without suppressing appetite suggests a genuine metabolic mechanism rather than the drug just making the animals feel sick or full. It’s a meaningfully different result than most weight-related interventions produce in early testing.
A follow-up line of research added another layer. A study in Scientific Reports combined NNMT inhibition with a calorie-reduced diet in diet-induced obese mice and tracked the gut microbiome alongside adiposity. The combination treatment produced faster reductions in fat mass and liver pathology markers than diet change alone, and the mice’s microbiome shifted toward a profile with more Lactobacillus, a change generally associated with improved metabolic health in rodent models.
The value of these studies isn’t that they prove a fat-loss drug. It’s that they validate NNMT as a target worth pursuing, and they do it with a consistent, reproducible signal across two independent research groups using different endpoints.
Here’s what the studies didn’t show, and it’s a longer list than most product pages will admit:
That’s a real evidence base, and it’s also a preclinical one. The distance between “reversed obesity in mice via injection” and “safe, effective oral supplement for humans” is where a lot of research chemical marketing conveniently stops looking.
This is the question that separates serious researchers from people just reading vendor copy, because the pharmacokinetic data tell a more complicated story than most product pages suggest.
Membrane permeability testing, using standard PAMPA and Caco-2 assay methods, showed that 5-Amino-1MQ has favorable passive and active transport characteristics compared to other methylquinolinium analogues tested in the same structure-activity series. In plain terms: at the cellular membrane level, the molecule crosses barriers efficiently. That’s a good sign for any compound intended to reach intracellular targets like NNMT.
But permeability at the cell membrane is not the same thing as bioavailability after you swallow a capsule. Oral bioavailability depends on surviving stomach acid, resisting first-pass metabolism in the liver, and reaching systemic circulation intact, none of which a Caco-2 assay directly measures.
Here’s where species differences complicate everything. A pharmacokinetic study by Awosemo and colleagues reported oral bioavailability in rats of roughly 38% using a validated LC-MS/MS assay, with measurable Cmax and AUC values following a single oral dose. That’s a genuinely usable number for a small molecule. Mice, however, showed considerably poorer oral absorption in the same line of research, which is exactly why the primary efficacy studies in mice relied on injection rather than oral dosing.
That split matters enormously for anyone reading a consumer label that promises oral efficacy:
Pro Tip: If a product page claims “clinically studied” oral dosing, ask which species and which route that study actually used. Rat oral bioavailability data is not the same as human oral bioavailability data, and neither is a substitute for a human PK study that hasn’t been done.
The honest summary: the molecule’s membrane properties are promising, the rat data hints at oral feasibility, and the mouse data shows the opposite pattern in the species the fat-loss studies actually used. Anyone selling capsules with a specific oral dose is making a claim the current research doesn’t fully support.
Ask “is 5-Amino-1MQ safe” and the honest answer is that nobody has run the controlled human trial that would let anyone say yes or no with confidence. What exists instead is a mix of preclinical toxicity signals, anecdotal consumer reports, and regulatory silence.
In vitro work has shown cytotoxic effects at high concentrations, well above the IC50 range used to demonstrate NNMT inhibition, which is a fairly standard finding for small molecules and not by itself alarming. It does mean dosing margins matter, and margins established in a petri dish don’t automatically translate to a safe human dose. Consumer and forum reports mention mild, anecdotal issues including gastrointestinal upset, headache, and occasional allergic-type reactions, but none of this comes from systematic, controlled reporting. There’s no adverse event database, no phase I safety trial, and no dose-escalation study establishing a maximum tolerated dose in humans.
A few standard precautions apply here regardless of the compound’s novelty:
On the regulatory side, the facts are unambiguous even if the marketing around them isn’t. 5-Amino-1MQ has no FDA approval for any use, human or otherwise, and no registered clinical trials appear for it as an NNMT inhibitor in human subjects. It’s sold as a research chemical, meaning “research use only” isn’t a legal loophole vendors invented. It’s the actual regulatory category the compound occupies: intended for laboratory investigation, not human consumption, regardless of what capsule packaging implies. Non-approved compounds like this one also fall under WADA’s broader S0 classification for substances lacking regulatory approval, which carries implications for anyone in competitive sport.
None of that means the compound is dangerous. It means the safety profile hasn’t been established by the kind of controlled human data that would let anyone make a confident claim either way, and the gap between “no reported serious harm” and “proven safe” is a wide one that vendor marketing routinely blurs.
If you’re weighing this compound for research purposes, the dose math is the first thing to get honest about. The mouse efficacy studies used subcutaneous and intraperitoneal injection at doses in the range of 20 mg/kg, administered multiple times daily. Scale that to a 70-kilogram human using standard interspecies conversion, and you get a number that looks nothing like the 50 to 150 mg per day range printed on most consumer capsule labels, and it’s not just about total milligrams. Injection bypasses first-pass liver metabolism entirely, while an oral capsule doesn’t. Comparing an injected mouse dose to an oral human dose without accounting for route, absorption, and species-specific PK is comparing two different experiments, not scaling one protocol into another.
Here’s a practical framework for thinking through this responsibly:
The gap between what a mouse study protocol looks like and what a supplement label promises is the single biggest source of confusion around this compound. Closing that gap requires reading the primary research, not the marketing copy built on top of it.
Given that 5-Amino-1MQ is chemically simple and unregulated as a consumer product, supplier quality is doing most of the work of protecting research integrity. A few non-negotiables:
Synthrolab approaches this the same way it handles every compound in its catalog: independent batch testing with a certificate of analysis attached to the actual lot shipped, not a marketing average. That standard applies across Synthrolab’s peptide and compound categories, where COA documentation is treated as baseline, not a premium add-on. None of this is a substitute for the fact that 5-Amino-1MQ remains a research chemical intended for laboratory investigation, not a medical product, and nothing here should be read as a recommendation for human use outside a research setting.
The mechanistic case for NNMT inhibition is genuinely one of the more interesting threads in metabolic research right now, and I don’t think that’s overstated. Two independent research groups getting consistent results in diet-induced obese mice, with a specific enzyme target and a plausible NAD+/SAM mechanism behind it, is a stronger starting position than most compounds circulating in the research chemical space ever reach.
What frustrates me is watching that legitimate science get flattened into supplement marketing before anyone’s run the studies that would actually justify it. A rat oral bioavailability number gets stretched into an implied human claim. An injected mouse dose gets rebranded as a milligram range for a capsule. None of that is what the researchers who ran these studies claimed, and treating 5-Amino-1MQ as a proven fat-loss product misrepresents genuinely promising early-stage science.
The right next step isn’t more marketing copy. It’s a properly designed human pharmacokinetic study, followed by a real safety trial, before anyone can responsibly talk about doses or outcomes in people. Until then, this compound belongs in the research category it’s actually sold under. If you’re doing that kind of work and need compounds with real batch documentation behind them, that’s exactly the conversation Synthrolab exists to support.
— Mitch
If you’ve read this far, you already understand why sourcing quality matters as much as the mechanism itself. A compound with this little human data demands more scrutiny of what’s actually in the vial, not less, and that starts with a supplier willing to show you a real, batch-specific certificate of analysis rather than a stock photo of a lab coat.
Synthrolab is built around that exact standard: research-grade compounds with independent purity testing on the actual batch you receive, not an average pulled from marketing materials. For researchers exploring NNMT inhibition alongside other metabolic pathways, Synthrolab’s guide to peptide quality and testing standards walks through exactly what a COA should include and how to read one before you order. If you’re planning a broader research protocol involving NAD+ pathways, mitochondrial function, or longevity mechanisms, the Test Builder tool helps structure what compounds and assays fit your specific research question. Everything Synthrolab sells is intended strictly for laboratory research, not human consumption, and that boundary shapes how every product on the site is documented and shipped. Start by reviewing the current research compound catalog to see what’s available with full batch documentation attached.
The PMC-indexed study on selective NNMT inhibitors is the foundational paper behind nearly every claim made about 5-Amino-1MQ, and it’s worth reading in full rather than trusting a summary. The Scientific Reports microbiome study adds a second, independent data point on adiposity and gut bacteria shifts. For chemical identity and purity specifications, Sigma-Aldrich’s product page is the reference standard. For a broader evidence summary including the rat pharmacokinetic data, PeptideInsight’s overview pulls together findings that are otherwise scattered across separate papers.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
